SPA
TNGX icon

Sherbrooke Park Advisers’s Tango Therapeutics TNGX Stock Holding History

Sherbrooke Park Advisers’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,307
Closed -$38K – 934
2024
Q4 		$38K Buy
+12,307
New +$57.1K 0.01% 714
2024
Q2 		– Sell
-11,467
Closed -$91K – 1201
2024
Q1 		$91K Buy
+11,467
New +$123K 0.02% 798

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sherbrooke Park Advisers's TNGX Position: Q1 2025 in Review

Sherbrooke Park Advisers sold out of Tango Therapeutics (TNGX) in Q1 2025, closing a stake of 12,307 shares — an estimated $38K sold.

Sherbrooke Park Advisers first reported a position in TNGX in Q1 2024 and held it in 2 quarters. The position peaked at $91K in Q1 2024. 122 funds tracked by Wall St. Rank hold TNGX as of Q1 2025.

  • Sherbrooke Park Advisers reported no remaining Tango Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 12,307 Tango Therapeutics shares in Q1 2025, an estimated $38K.
  • Sherbrooke Park Advisers first reported a position in Tango Therapeutics in Q1 2024 and held it in 2 quarters.
  • Sherbrooke Park Advisers's Tango Therapeutics position peaked at $91K in Q1 2024.
  • 122 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q1 2025, filed 15 May 2025.